Holen Sie sich die Stockscreener-App
33.21
0.21%
0.07
Handel nachbörslich:
33.21
Schlusskurs vom Vortag:
$33.14
Offen:
$33.16
24-Stunden-Volumen:
3.52M
Relative Volume:
1.10
Marktkapitalisierung:
$4.13B
Einnahmen:
$715.22M
Nettoeinkommen (Verlust:
$-250.10M
KGV:
-6.3257
EPS:
-5.25
Netto-Cashflow:
$-205.58M
1W Leistung:
+0.06%
1M Leistung:
+20.81%
6M Leistung:
-16.41%
1J Leistung:
-39.57%
1-Tages-Spanne:
$32.89
$34.27
1-Wochen-Bereich:
$32.71
$35.70
52-Wochen-Spanne:
$24.34
$73.80
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Firmenname
Apellis Pharmaceuticals Inc
Sektor
Branche
Telefon
617-977-5700
Adresse
100 FIFTH AVENUE, WALTHAM, KY
Vergleichen Sie APLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
33.21 | 4.13B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-17 | Herabstufung | Goldman | Buy → Neutral |
| 2024-11-21 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-16 | Eingeleitet | William Blair | Outperform |
| 2024-05-31 | Eingeleitet | Piper Sandler | Neutral |
| 2024-02-05 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-02 | Eingeleitet | Mizuho | Neutral |
| 2023-10-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Bestätigt | Citigroup | Buy |
| 2023-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-17 | Fortgesetzt | Stifel | Buy |
| 2022-04-14 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-29 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-09-10 | Bestätigt | Credit Suisse | Neutral |
| 2021-09-10 | Bestätigt | Needham | Buy |
| 2021-09-10 | Bestätigt | Oppenheimer | Outperform |
| 2021-09-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-08-19 | Eingeleitet | Jefferies | Buy |
| 2021-08-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2020-11-19 | Eingeleitet | Needham | Buy |
| 2020-09-01 | Eingeleitet | Stifel | Buy |
| 2020-07-20 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-04-01 | Eingeleitet | Raymond James | Strong Buy |
| 2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-11 | Hochstufung | Wedbush | Underperform → Neutral |
| 2020-01-07 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-12-19 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-22 | Eingeleitet | Wedbush | Underperform |
| 2019-11-05 | Eingeleitet | Credit Suisse | Neutral |
| 2019-08-01 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Barclays PLC Raises Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Goldman Sachs Downgrades Apellis Pharmaceuticals (APLS) - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Downgraded by The Goldman Sachs Group to "Neutral" - MarketBeat
Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (20 Ratings) - Benzinga
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Mama's Creations Posts Weak Earnings, Joins EVgo, Red Cat Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Short Interest Down 5.9% in November - MarketBeat
State Street Corp Has $116.54 Million Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
There's No Escaping Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Muted Revenues Despite A 26% Share Price Rise - Simply Wall St
Should You Hold Apellis Pharmaceuticals (APLS)? - Insider Monkey
Old West Investment Management LLC Acquires Shares of 102,403 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 17,119 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Geographic Atrophy Market: Rapid Growth and Key Research - openPR
Apellis Pharmaceuticals Inc (APLS-Q) QuotePress Release - The Globe and Mail
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Apellis Pharmaceuticals Awards New Equity Incentives to Strengthen Executive Team - StockTitan
Cerity Partners LLC Acquires 23,749 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Fmr LLC Reduces Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Why Is Apellis Pharmaceuticals (APLS) Up 18.4% Since Last Earnings Report? - Yahoo Finance
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
42,000 Shares in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Bought by Erste Asset Management GmbH - MarketBeat
BNP Paribas Financial Markets Increases Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
HighVista Strategies LLC Increases Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Bellevue Group AG Sells 425,358 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Edgestream Partners L.P. Grows Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Braidwell LP Grows Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
APLSApellis Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
ROSEN, LEADING INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionAPLS - Marketscreener.com
Zacks Research Has Bearish Estimate for APLS FY2024 Earnings - MarketBeat
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - The Manila Times
Apellis Pharmaceuticals to Present at Evercore ISI and Citi Healthcare Conferences | APLS Stock News - StockTitan
Shareholders Can't Ignore US$6.6m Of Sales By Apellis Pharmaceuticals Insiders - Simply Wall St
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Sold by Algert Global LLC - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Apellis started at equal-weight at Morgan Stanley on geographic atrophy market - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Up 8.8%Should You Buy? - MarketBeat
Landscape Capital Management L.L.C. Invests $776,000 in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Deep Track Capital, LP Reduces Stake in Apellis Pharmaceuticals Inc - GuruFocus.com
Deep Track Capital, LP Increases Stake in Apellis Pharmaceuticals Inc. - GuruFocus.com
Jennison Associates LLC Sells 1,770,301 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Morgan Stanley Initiates Coverage of Apellis Pharmaceuticals (APLS) with Equal-Weight Recommendation - MSN
How to Take Advantage of moves in (APLS) - Stock Traders Daily
Morgan Stanley Begins Coverage on Apellis Pharmaceuticals (NASDAQ:APLS) - MarketBeat
A Glimpse Into The Expert Outlook On Apellis Pharmaceuticals Through 20 Analysts - Benzinga
Apellis Pharmaceuticals (FRA:1JK) Degree of Operating Lever - GuruFocus.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Sold by Victory Capital Management Inc. - MarketBeat
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y - MSN
Apellis Pharmaceuticals shares surge following Astellas Pharma’s FDA setback By Investing.com - Investing.com Australia
Apellis Pharmaceuticals shares surge following Astellas Pharma’s FDA setback - Investing.com India
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap UpTime to Buy? - MarketBeat
Finanzdaten der Apellis Pharmaceuticals Inc-Aktie (APLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):